BOSTON and SYDNEY — 07 February 2018— GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to confirm that, further to its announcement released on 23 January 2018, the attached proxy statement and notice of a special meeting of stockholders (Special Meeting) has been filed with the U.S. Securities and Exchange Commission. The proxy materials, including this proxy statement and the voting instruction cards will be mailed to stockholders on or about 8 February 2018.
The Special Meeting is to be held on Wednesday 21 February 2018 at 3:00pm United States Eastern Standard Time, (22 February 2018 at 7:00am Australian Eastern Daylight Time) at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Centre, Boston, Massachusetts 02111.
If not attending in person, the meeting can be accessed through a teleconference line.
Accessing via teleconference:
For those preferring to listen by telephone, please dial in five minutes prior to the start of the call. Regional dial in number are as follows:
United States Dial Toll Free 877.407.6184
Australia Dial Toll Free 1.800.687.004
Germany Dial Toll Free 0.800.182.0040
United Kingdom Dial Toll Free 0.800.756.3429
Switzerland Dial Toll Free 800.835.525
Other International Dial Toll 201.389.0877
About GI Dynamics
GI Dynamics®, Inc. (ASX:GID) is the developer of EndoBarrier, the first endoscopically-delivered device therapy for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale and is limited by federal law to investigational use only. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information please visit www.gidynamics.com.
This announcement contains forward-looking statements. These forward-looking statements are based on GI Dynamics management’s current estimates and expectations of future events as of the date of this announcement. Furthermore, the estimates are subject to several risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with our ability to continue to operate as a going concern, our ability to maintain compliance with our obligations under the Convertible Loan Note executed with Crystal Amber Fund Limited, obtaining and maintaining regulatory approvals required to market and sell our products; obtaining funding from third parties; the consequences of stopping the ENDO trial and the possibility that future clinical trials will not be successful or confirm earlier results; the timing and costs of clinical trials; the timing of regulatory submissions; the timing, receipt and maintenance of regulatory approvals; the timing and amount of other expenses; the timing and extent of third-party reimbursement; intellectual-property risk; risks related to excess inventory; and risks related to assumptions regarding the size of the available market, the benefits of our products, product pricing, timing of product launches, future financial results and other factors, including those described in our filings with the U.S. Securities and Exchange Commission. Given these uncertainties, one should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, unless we are required to do so by law.